Iterum Therapeutics (NASDAQ:ITRM) Cut to “Hold” at HC Wainwright

HC Wainwright downgraded shares of Iterum Therapeutics (NASDAQ:ITRM) from a buy rating to a hold rating in a research note published on Monday, MarketBeat reports.

Several other equities research analysts have also weighed in on ITRM. Weiss Ratings reissued a “sell (e+)” rating on shares of Iterum Therapeutics in a report on Monday, December 22nd. Maxim Group downgraded shares of Iterum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 4th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $9.00.

Iterum Therapeutics Price Performance

Shares of ITRM opened at $0.03 on Monday. Iterum Therapeutics has a 1 year low of $0.03 and a 1 year high of $1.42. The stock’s fifty day moving average price is $0.22 and its two-hundred day moving average price is $0.42. The firm has a market cap of $1.69 million, a PE ratio of -0.04 and a beta of 3.37.

Institutional Investors Weigh In On Iterum Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new position in shares of Iterum Therapeutics in the second quarter worth $92,000. OneDigital Investment Advisors LLC grew its position in shares of Iterum Therapeutics by 18.6% in the third quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock valued at $128,000 after purchasing an additional 30,000 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Iterum Therapeutics during the 3rd quarter valued at $32,000. Apollon Financial LLC raised its stake in shares of Iterum Therapeutics by 151.8% during the 4th quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock valued at $211,000 after purchasing an additional 380,000 shares during the period. Finally, Alchemi Wealth LLC purchased a new stake in Iterum Therapeutics during the 4th quarter worth about $90,000. Hedge funds and other institutional investors own 9.21% of the company’s stock.

About Iterum Therapeutics

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).